Logo for Artelo Biosciences Inc

Artelo Biosciences Investor Relations Material

Latest events

Logo for Artelo Biosciences Inc

Fireside Chat

Artelo Biosciences
Logo for Artelo Biosciences

Q1 2024

13 May, 2024
Logo for Artelo Biosciences

Fireside Chat

23 Apr, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Artelo Biosciences Inc

Access all reports
Artelo Biosciences Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary therapeutics. These therapeutics are designed to modulate lipid-signaling pathways, including the endocannabinoid system, aiming to address significant unmet medical needs across various diseases and conditions such as anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Artelo is advancing a diverse portfolio of product candidates, including ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist for treating anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal targeting inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor intended for breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company is headquartered in Solana Beach, California, and its shares are listed on the Nasdaq.